导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 35.41% | 85/4773 |
| 近一周 | 1.51% | 298/5465 |
| 近一月 | -3.01% | 2095/5421 |
| 近一季 | -11.92% | 3991/5231 |
| 近半年 | 28.64% | 83/4920 |
| 近一年 | 43.06% | 106/4394 |
| 近两年 | 202.35% | 82/2954 |
| 近三年 | 157.07% | 35/2253 |
| 成立以来 | 18.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.58% 2372/4961 |
81.39% 175/5312 |
- - |
- - |
| 2025 | 61.61% 197/4813 |
2.97% 1228/3635 |
2.89% 1288/4076 |
54.95% 198/4524 |
-1.55% 2965/4813 |
| 2024 | 20.68% 448/3463 |
-3.25% 1481/2808 |
- 664/3014 |
14.66% 1934/3129 |
8.78% 370/3463 |
| 2023 | 5.22% 196/2656 |
23.56% 110/2280 |
-2.62% 624/2385 |
-9.72% 1883/2515 |
-3.15% 615/2655 |
| 2022 | -29.71% 1612/2207 |
-22.12% 1686/1919 |
0.81% 1525/2016 |
-15.14% 1224/2113 |
5.50% 461/2208 |
| 2021 | 9.10% 460/1822 |
-6.76% 1038/1255 |
15.09% 237/1330 |
-7.46% 1053/1466 |
9.86% 109/1822 |
| 2020 | 22.05% 678/1250 |
-1.01% 197/1028 |
22.28% 212/1067 |
-0.56% 1057/1164 |
1.40% 1033/1184 |
| 2019 | 45.23% 154/1092 |
35.70% 86/739 |
-10.81% 749/788 |
9.90% 51/850 |
9.19% 247/918 |
| 2018 | -32.62% 537/834 |
- - |
-16.58% 556/631 |
-7.68% 465/660 |
-12.79% 487/682 |
| 2017 | 5.02% 363/714 |
- - |
- - |
- - |
- - |
| 2016 | -23.75% 465/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 景顺中证科技传媒通信150ETF联接 VS. 长安沪深300非周期A(740101) |